- R&D and Production Infrastructure: Anatolia operates within a 15,000 m² R&D and production facility where the design, development, and manufacture of Real-Time PCR kits, nucleic acid extraction kits, rapid antigen tests, automated extraction instruments, and PCR Setup robots are carried out. Our R&D Center, accredited by the Republic of Türkiye Ministry of Industry and Technology, continues to deepen its technical expertise and automation-based platform capabilities.
- 2025 Project Portfolio: Between January 1 and December 31, 2025, the R&D Center conducted studies on 21 different projects. During this period, the “TR.AQUA” project has been successfully carried out under the TÜBİTAK 1004 program. Additionally, new project applications were submitted under TÜBİTAK TEYDEB 1501 and TAGEM R&D Support Programs.
- Product Development and Commercialization: In 2025, the development of a total of 93 products was completed and transferred to production for commercialization. The distribution of these products is as follows: 55 Real-Time PCR kits (human health), 29 Real-Time PCR kits (food and veterinary), 6 new rapid cassette tests, 2 extraction robots with integrated kits, and 1 sample transport solution.
- Full Automation and UNIO 448: In 2025, UNIO 448 sample-to-result fully automated diagnostic system was launched as a tangible output of our vision for full automation. The adaptation of our existing product portfolio to this platform has been completed, increasing standardization and rapid response capacity for high sample volumes.
- A New Approach to Food Analysis: M8 and M16 Automated Extraction Systems, with processing capacities of 8 and 16 samples, respectively, were developed to minimize manual processes for food safety laboratories. These systems offer high efficiency and traceability in food adulteration detection and pathogen screening processes.
- Human Resources and Academic Collaborations: The R&D team grew by 7.2% through the recruitment of new engineers and molecular biologists, increasing its personnel from 97 to 104. Furthermore, validation collaborations on sepsis, HPV, and HBV have been initiated and are ongoing with several universities both domestically and abroad.
